Advertisement

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia

  • H. K. LuckhoffEmail author
  • S. Kilian
  • M. R. Olivier
  • L. Phahladira
  • F. Scheffler
  • S. du Plessis
  • B. Chiliza
  • L. Asmal
  • R. Emsley
Original Article

Abstract

Few studies have investigated the longitudinal effects of treatment-emergent metabolic syndrome changes on cognitive performance in first-episode psychosis. The aim of the present study was to determine the associations between changes in metabolic syndrome constituent component over 12 months of treatment and end-point cognitive performance in schizophrenia spectrum disorders. This single site-cohort study included 72 minimally treated or antipsychotic-naïve first-episode patients. Cognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). Our primary objective of interest was the relationship between metabolic syndrome constituent component changes over 12 months of treatment and end-point cognitive performance. Secondary objectives included investigating whether this relationship was affected by age, sex, antipsychotic dose, treatment duration and substance use. Weight gain predicted better overall cognition (p = 0.02) at end-point, adjusting for age, sex, substance use, baseline cognitive score and BMI, modal antipsychotic dose and treatment duration. Weight loss (p = 0.04) and substance use (p = 0.01) were both associated with poorer working memory performance at end-point. Low baseline BMI showed differential effects on end-point working memory performance in substance users (unfavorable) compared to non-users (favorable) (p < 0.05). In conclusion, weight gain over the course of antipsychotic treatment is associated with better overall cognitive performance and the working memory domain in first-episode schizophrenia spectrum disorder patients. In contrast, low baseline BMI may represent an unfavorable marker in substance users, who demonstrated weight loss compared to non-users.

Keywords

First-episode schizophrenia spectrum disorders Cognitive performance Working memory MCCB Weight gain 

Notes

Acknowledgements

This study was funded by New Partnership for Africa’s Development (NEPAD) grant, through the Department of Science and Technology of South Africa, the Medical Research Council of South Africa ‘SHARED ROOTS’ Flagship Project Grant no.MRC-RFA-IFSP-01-2013 (Grantholder S Seedat) and an unrestricted grant from Lundbeck International.

Compliance with ethical standards

Conflicts of interest

Bonginkosi Chiliza has received honoraria from Lundbeck, Mylan and Sandoz for speaking at educational meetings. Robin Emsley has participated in speakers/advisory boards and received honoraria from Janssen, Lundbeck, Servier and Otsuka. Hilmar Luckhoff, Lebogang Phahladira, Freda Scheffler, Stefan du Plessis, Laila Asmal, Riaan Oosthuizen, and Sanja Kilian declare that they have no conflicts of interest.

References

  1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM). Washington DC: American Psychiatric AssociationGoogle Scholar
  2. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62(4):231–238PubMedGoogle Scholar
  3. Bogaty SER, Lee RSC, Hickie IB, Hermens DF (2018) Meta-analysis of neurocognition in young psychosis patients with current cannabis use. J Psychiatr Res 99:22–32PubMedGoogle Scholar
  4. Bora E (2016) Differences in cognitive impairment between schizophrenia and bipolar disorder: considering the role of heterogeneity. Psychiatry Clin Neurosci 70(10):424–433PubMedGoogle Scholar
  5. Bora E, Akdede BB, Alptekin K (2017a) Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med 47(14):2401–2413PubMedGoogle Scholar
  6. Bora E, Akdede BB, Alptekin K (2017b) The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med 47(6):1030–1040PubMedGoogle Scholar
  7. Botis AC, Miclutia I, Vlasin N (2016) Cognitive function in female patients with schizophrenia and metabolic syndrome. Eur Psychiatry 33:97Google Scholar
  8. Boyer L, Richieri R, Dassa D, Boucekine M, Fernandez J, Vaillant F, Padovani R, Auquier P, Lancon C (2013) Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res 210(2):381–386PubMedGoogle Scholar
  9. Chiliza B, Asmal L, Oosthuizen P, van Niekerk E, Erasmus R, Kidd M, Malhotra A, Emsley R (2015) Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Eur Psychiatry 30(2):277–283PubMedGoogle Scholar
  10. Chukhin E, Terevnikov V, Takala P, Hakko H, Putkonen H, Räsänen P, Stenberg JH, Eronen M, Joffe G (2016) Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism? Nord J Psychiatry 70(3):190–194PubMedGoogle Scholar
  11. Dickinson D, Harvey PD (2009) Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 35(2):403–414PubMedGoogle Scholar
  12. Elias PK, Elias MF, D'Agostino RB, Sullivan LM, Wolf PA (2005) Serum cholesterol and cognitive performance in the Framingham heart study. Psychosom Med 67(1):24–30PubMedGoogle Scholar
  13. First MB, Spitzer RLGM, Williams LBW (1994) Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). In (Anonymous), New York State Psychiatric Institute, Biometrics Research: New YorkGoogle Scholar
  14. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL (2010) The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 167(10):1232–1239PubMedGoogle Scholar
  15. Girgis RR, Javitch JA, Lieberman JA (2008) Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 13(10):018–929Google Scholar
  16. Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N (2015) Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract 21(3):190–197PubMedGoogle Scholar
  17. Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J (2013) The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 13:109PubMedPubMedCentralGoogle Scholar
  18. Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA (2011) Serotonergic anti-obesity agents: past experience and future prospects. Drugs 71(17):2247–2255PubMedGoogle Scholar
  19. Higgs S, Spetter MS (2018) Cognitive control of eating: the role of memory in appetite and weight gain. Curr Obes Rep 7:50–59PubMedPubMedCentralGoogle Scholar
  20. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25(3):25–258Google Scholar
  21. Krakowski M, Czobor P (2011) Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res 130(1–3):27–33PubMedGoogle Scholar
  22. Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, Cherath L, Valdez G, Wance D (2012) Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res 142(1–3):171–176PubMedGoogle Scholar
  23. Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8(3):218–226PubMedGoogle Scholar
  24. Luckhoff H, Phahladira L, Scheffler F, Asmal L, du Plessis S, Chiliza B, Kilian S, Emsley R (2018) Weight gain and metabolic change as predictors of symptom improvement in fist-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophrenia Research pii: S0920-9964(18)30682-0Google Scholar
  25. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A (2003) Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measures Study in Schizophrenia. Can J Psychiatr 48(10):689–694Google Scholar
  26. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 39(2):306–318PubMedGoogle Scholar
  27. Nasrallah H, Blom TJ (2015) Elevated cholesterol and triglycerides are associated with better cognitive functioning in schizophrenia: data from the CATIE study. Presentation at: APA 2015. May 16-20, 2015; Toronto, CanadaGoogle Scholar
  28. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L, Miller R (1999) Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 25(2):321–335PubMedGoogle Scholar
  29. Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D (2007) Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berlin) 191(4):1015–1022Google Scholar
  30. Novick D, Haro JM, Suarez D, Vieta E, Naber D (2009) Recovery in the outpatient setting: 36-month results from the schizophrenia outpatients health outcomes (SOHO) study. Schizophr Res 108(1–3):223–230PubMedGoogle Scholar
  31. Nuechterlein KH, Green MF (2006) MATRICS consensus battery manual 2006. MATRICS Assessment Inc., Los AngelesGoogle Scholar
  32. Olivier MR, Killian S, Chiliza B, Asmal L, Schoeman R, Oosthuizen PP, Kidd M, Emsley R (2015) Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med 45(13):2873–2883PubMedGoogle Scholar
  33. Orosco M, Rouch C, Gerozissis K (2000) Activation of hypothalamic insulin by serotonin is the primary event of the insulin-serotonin interaction involved in the control of feeding. Brain Res 872(1–2):64–70PubMedGoogle Scholar
  34. Panariello F, Javaid N, Teo C, Monda M, Viggiano A, De Luca V (2011) The role of orexin system in antipsychotics induced weight gain. Curr Psychiatr Rev 7(1):18–21Google Scholar
  35. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK (2018) The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurosci 11:741PubMedPubMedCentralGoogle Scholar
  36. Sanchez-Gutierrez T, Fernandez-Castilla B, Barbeito S, Becerra JA, Calvo A (2018) Comparison between cannabis users and non-users patients with first-episode psychosis in neurocognitive functioning: a meta-analysis. Schizophr Bull 44(1):255–256Google Scholar
  37. Scheffler F, Kilian S, Chiliza B, Asmal L, Phahladira L, du Plessis S, Kidd M, Murray RM, Di Forti M, Seedat S, Emsley R (2018) Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders. Schizophr Res 199:90–95PubMedGoogle Scholar
  38. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ (2006) Serotonin and human cognitive performance. Curr Pharm Des 12(20):2473–2486PubMedGoogle Scholar
  39. Shemesh E, Rudich A, Harman-Boehm I, Cukieman-Yaffe T (2012) Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 97(2):366–376PubMedGoogle Scholar
  40. Smith PJ, Blumenthal JA, Babyak MA, Craighead L, Welsh-Bohmer KA, Browndyke JN, Strauman TA, Sherwood A (2010) Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension 55(6):1331–1338PubMedPubMedCentralGoogle Scholar
  41. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J (2011) Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187(1–2):42–48PubMedGoogle Scholar
  42. Storch-Jakobsen A, Speyer H, Nørgaard HCB, Hjorthøj C, Krogh J, Mors O, Nordentoft M (2018) Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - baseline and two-years findings from the CHANGE trial. Schizophr Res 199:96–102PubMedGoogle Scholar
  43. Strac D, Pivac N, Mück-Šeler D (2016) The serotonergic system and cognitive function. Transl Neurosci 7(1):35–49Google Scholar
  44. Umbriaco D, Garcia S, Beaulieu C, Descarries L (1995) Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus 5(6):605–620PubMedGoogle Scholar
  45. Wiesbeck GA, Weijers HG, Wodarz N, Lesch OM, Glaser T, Boening J (2003) Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics. Arch Womens Ment Health 6:259–262PubMedGoogle Scholar
  46. Wysokinski A, Dzienniak M, Kłoszewska I (2013) Effect of metabolic abnormalities on cognitive performance and clinical symptoms in schizophrenia. Archives of Psychiatry and Psychotherapy 4:13–25Google Scholar
  47. Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012) The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 38(2):316–330PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • H. K. Luckhoff
    • 1
    Email author
  • S. Kilian
    • 1
  • M. R. Olivier
    • 1
  • L. Phahladira
    • 1
  • F. Scheffler
    • 1
  • S. du Plessis
    • 1
  • B. Chiliza
    • 2
  • L. Asmal
    • 1
  • R. Emsley
    • 1
  1. 1.Department of Psychiatry, Faculty of Medicine and Health SciencesStellenbosch UniversityCape TownSouth Africa
  2. 2.Department of Psychiatry, Nelson R Mandela School of MedicineUniversity of Kwazulu-NatalDurbanSouth Africa

Personalised recommendations